Kaifeng Medicine Co, Kaifeng Hengyu Pharmaceutical Co and Kaifeng Songbaotang Pharmaceutical are three new Sino-foreign joint ventures established in Kaifeng, Henan Province, China.
The first, Kaifeng Medicine, registered at $1.5 million, will produce western drugs, traditional Chinese medicines and tonics, reports China Medipharm Insight. Kaifeng Hengyu, capitalized at $2.7 million, will focus on doxycycline and Kaifeng Songbaotang, capitalized at $2 million, will produce mainly gelatins such as antler gelatin and donkey-hide gelatin.
CMI points out that the establishment of these three JVs indicates that the inland areas of China are strengthening their cooperation with foreign companies under the encouragement and support of the country's government.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze